Loading stock data…
PRLD
$4.50-0.17 (-3.71%)
Market OpenUpdated 10:13 AM EDT
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prelude Therapeutics Incorporated in the Healthcare sector is trading at $4.67. The stock is currently near its 52-week high of $5.54, remaining 118.2% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why PRLD maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.50
Potential Upside
5%
Whystock Fair Value$4.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$270.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-174.31%
Volume
Today's trading volume
142,626
Recent News
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
Prelude Therapeutics (NASDAQ:PRLD) is one of the best biotech penny stocks to buy in 2026. On April 20, Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class, oral KAT6A degrader. Designed for HR+/HER2- breast cancer, the candidate demonstrated the ability to achieve complete tumor regressions as a monotherapy across multiple models, including those resistant […]
Myriad Genetics And 2 Other Penny Stocks To Watch Closely
The United States market has shown robust growth, rising 3.5% over the last week and 31% over the past year, with earnings expected to increase by 16% annually in the coming years. In such a thriving market, identifying stocks with strong financials becomes crucial for investors seeking both affordability and growth potential. Although often considered a term from bygone eras, penny stocks continue to offer intriguing opportunities within smaller or newer companies that might surprise...
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer. Brian Piper joined the company with over 25 years of biopharmaceutical experience, most recently serving as CFO of Scorpion Therapeutics and its spin-off, […]
Definitive Healthcare And 2 Other Promising Penny Stocks
As the U.S. stock market edges higher with the S&P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future trends. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for those seeking growth at lower price points. Though considered a niche area, these stocks can shine when backed by solid financial health and fundamentals,...
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week
Key Insights Prelude Therapeutics' significant retail investors ownership suggests that the key decisions are...